Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid Tumors

ClinicalTrials.gov ID: NCT04064359

Public ClinicalTrials.gov record NCT04064359. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jun 27, 2026, 7:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase I, Open-label, Dose Finding Study to Assess the Safety, Tolerability, PK, and Preliminary Efficacy of OBT076, a CD205-directed ADC, in Recurrent and/or Metastatic CD205+ Solid Tumors

Study identification

NCT ID: NCT04064359
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: Oxford BioTherapeutics Ltd; Industry
Enrollment: 200 participants

Conditions and interventions

Conditions

Solid Tumor

Interventions

OBT076, a CD205-directed antibody-drug conjugate Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 24, 2019
Primary completion: Dec 30, 2026
Completion: Dec 30, 2027
Last update posted: Sep 15, 2025

2019 – 2027

United States locations

U.S. sites: 10
U.S. states: 9
U.S. cities: 10

Facility	City	State	ZIP	Site status
Mayo Clinic	Phoenix	Arizona	85084	Completed
Cedars-Sinai	Los Angeles	California	90048	Completed
UCLA	Santa Monica	California	90404	Completed
Moffitt Cancer Center	Tampa	Florida	33612	Completed
The State University of Iowa	Iowa City	Iowa	52242	Active, not recruiting
St. Elizabeth Healthcare	Edgewood	Kentucky	41017	Completed
University of Mississippi Medical Center	Jackson	Mississippi	39216	Completed
Quantum Santa Fe	Santa Fe	New Mexico	87505	Completed
Columbia University Medical Center	New York	New York	10032	Completed
University of Pittsburgh	Pittsburgh	Pennsylvania	15260	Completed

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 17 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT04064359, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 15, 2025 · Synced Jun 27, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04064359 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →